Valacyclovir for the Prevention of Cytomegalovirus Disease after Renal Transplantation
Open Access
- 13 May 1999
- journal article
- research article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 340 (19) , 1462-1470
- https://doi.org/10.1056/nejm199905133401903
Abstract
Cytomegalovirus (CMV) disease is a major complication of organ transplantation. We hypothesized that prophylactic treatment with valacyclovir would reduce the risk of CMV disease.Keywords
This publication has 32 references indexed in Scilit:
- Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV-seropositive liver transplant recipientsTransplant International, 1997
- Management of Cytomegalovirus Infection IN Solid-Organ Transplant RecipientsImmunological Investigations, 1997
- Prevention of cytomegalovirus disease in transplant recipientsThe Lancet, 1995
- Adverse Effects and Drug Interactions of Clinical Importance with Antiviral DrugsDrug Safety, 1994
- A PROSPECTIVE RANDOMIZED STUDY OF ACYCLOVIR VERSUS GANCICLOVIR PLUS HUMAN IMMUNE GLOBULIN PROPHYLAXIS OF CYTOMEGALOVIRUS INFECTION AFTER SOLID ORGAN TRANSPLANTATION1,2Transplantation, 1994
- THE IMPACT OF ACUTE REJECTION EPISODES ON LONG-TERM GRAFT FUNCTION AND OUTCOME IN 1347 PRIMARY RENAL TRANSPLANTS TREATED BY 3 CYCLOSPORINE REGIMENSTransplantation, 1993
- THE INCIDENCE AND IMPACT OF EARLY REJECTION EPISODES ON GRAFT OUTCOME IN RECIPIENTS OF FIRST CADAVER KIDNEY TRANSPLANTSTransplantation, 1992
- TREATMENT OF INVASIVE CYTOMEGALOVIRUS DISEASE IN SOLID ORGAN TRANSPLANT PATIENTS WITH GANCICLOVIRTransplantation, 1991
- A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal AllograftsNew England Journal of Medicine, 1989
- In vitro susceptibility of cytomegalovirus isolates from immunocompromised patients to acyclovir and ganciclovirDiagnostic Microbiology and Infectious Disease, 1987